Browsing Tag
BofA Securities
16 posts
Could United Community Banks’ Navitas exit become a regional banking playbook?
Find out how United Community Banks’ $1.9bn Navitas sale could affect UCB stock, capital strength and regional banking strategy today!
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
Quantinuum IPO closes at $1.68bn, but QNT trading shows investors want proof beyond quantum hype
Quantinuum raised $1.68bn, but QNT’s early trading asks the real question: can quantum computing turn promise into revenue?
Ambiq Micro (NYSE: AMBQ) rips 45% on Q1 beat as edge AI demand outruns guidance
AMBQ just printed 75% Q2 growth guidance into a market modelling 36%. The on-device AI silicon thesis is suddenly the only chip trade that does not need a hyperscaler order.
Why Life360 (ASX: 360) is leading ASX 200 gainers ahead of the May 11 Q1 result
Life360 leads the ASX 200, yet shares sit 62% below 2025 highs. The May 11 Q1 print is where the Nativo bet either works or breaks.
Suja Life files for Nasdaq IPO as better-for-you beverage growth meets public market scrutiny
Suja Life has filed for a Nasdaq IPO. Read why its growth, debt load, brand mix, and category timing matter more than the filing itself.
ICICIBANK at Rs 1,310: 38 analysts say buy. April 18 decides.
ICICI Bank (NSE: ICICIBANK) Q4 FY26 results on April 18. PAT consensus ₹11,500 to 12,200 Cr. Analyst targets up to ₹2,040. Key risks, iMobile Pay, and dividend outlook covered.
A $560m test for the diabetes device market as MiniMed prepares to trade on Nasdaq
MiniMed prices its IPO at $20 per share, raising $560M as Medtronic plc spins out its diabetes unit. Discover what the move means for the diabetes technology market.
Sealed Air Corporation (NYSE: SEE) wins stockholder approval for $10.3bn acquisition by CD&R
Sealed Air Corporation wins stockholder approval for its $10.3B CD&R buyout. Discover what this means for packaging markets and investors. Read more.
Lilly to acquire Ventyx Biosciences (Nasdaq: VTYX) in a high-conviction bet on oral inflammation therapies
Eli Lilly is acquiring Ventyx Biosciences for $1.2B to advance oral inflammation therapies. Find out what this means for biotech M&A and chronic care strategy.